证券代码：000788 证券简称：北大医药 公告编号：2026-012 包装规格：lkg/袋，5kg/袋，10kg/袋 药品生产企业：北大医药股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，北大医药股份有限公司（以下简称"公司"）收到国家药品监督管理 局核准签发的《化学原料药上市申请批准通知书》。现将相关情况公告如下： 一、药品基本情况 药品通用名称：帕利哌酮 英文名/拉丁名：Paliperidone 北大医药股份有限公司 关于获得《化学原料药上市申请批准通知书》的公告 审批主要结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册。 二、药品的其他相关情况 帕利哌酮是利培酮的主要活性代谢产物,是第二代抗精神病药物，控制作用 强，亲和力、耐受性及药效均较高，主要适用于成人及12-17岁青少年（体重≥ 29Kg）精神分裂症的治疗。 三、对公司的影响 《化学原料药上市申请批准通知书》 特此公告。 北大医药股份有限公司 帕利哌酮原料药的获批，将有利于公司进一步推进"原料制剂一体化"战略， 与制剂产品形成协 ...

证券代码：000788 证券简称：北大医药 公告编号：2026-011 北大医药股份有限公司 关于公司高级管理人员离任的公告 陈祥洪先生担任公司副总裁期间，恪尽职守、勤勉尽职，公司及董事会对陈 祥洪先生在任职期间作出的贡献表示衷心感谢！ 二、备查文件 《高级管理人员辞职报告》 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、高级管理人员离任情况 北大医药股份有限公司（以下简称"公司"）董事会于近日收到副总裁陈祥 洪先生的书面辞职报告。陈祥洪先生因个人原因申请辞去公司副总裁职务，且不 再担任公司任何职务。 陈祥洪先生原定任期为 2024 年 6 月 27 日至 2027 年 6 月 26 日。根据《深圳 证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号—— 主板上市公司规范运作》及《公司章程》等相关规定，陈祥洪先生的辞职不会影 响公司生产经营工作的正常开展，其辞职报告自送达公司董事会之日起生效。 董 事 会 截至本公告披露日，陈祥洪先生未直接或间接持有公司股票，不存在应当履 行而未履行的承诺事项。 ...

北大医药股份有限公司（以下简称"公司"或"本公司"）2025 年前三季 度权益分派方案已获 2026 年 1 月 28 日召开的 2026 年第一次临时股东会审议通 过，现将权益分派事宜公告如下： 一、股东会审议通过利润分配方案等情况 证券代码：000788 证券简称：北大医药 公告编号：2026-010 北大医药股份有限公司 2025年前三季度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 1.公司2026年第一次临时股东会审议通过的2025年前三季度利润分配方案 为：以 2025 年 9 月 30 日的总股本 595,987,425 股为基数,以可供股东分配的利 润向公司 全体股东每 10 股派发现 金 1.68 元（含税 ），总计派发红 利 100,125,887.40 元（含税。计算公式为：总股本 595,987,425 股÷10 股×1.68 元），本次利润分配不送红股，不以资本公积金转增股本。 2.若在分配预案实施前公司总股本由于可转债、股份回购、股权激励、再融 资新增股份上市等原因发生变化的，将按照分配总额不变的原则对分配比例进 ...

Core Viewpoint - The report highlights the growth in the chemical raw materials and products manufacturing industry in China, indicating a positive trend in the number of enterprises and overall market potential from 2026 to 2032 [1] Industry Summary - As of January to December 2025, the number of enterprises in the chemical raw materials and products manufacturing industry reached 27,102, an increase of 815 compared to the previous year, representing a year-on-year growth of 3.1% [1] - This sector accounts for 5.15% of the total industrial enterprises in China, reflecting its significance within the broader industrial landscape [1] - The report is based on data from the National Bureau of Statistics and compiled by Zhiyan Consulting, a leading industry consulting firm in China [1] Company Summary - The report mentions several listed companies in the chemical sector, including Hainan Haiyao (000566), Northeast Pharmaceutical (000597), and others, indicating a diverse range of players in the market [1] - Zhiyan Consulting provides comprehensive industry research reports, business plans, feasibility studies, and customized services, emphasizing its role in supporting investment decisions in the chemical industry [1]

Group 1 - The company expects a decline in operating performance for the year 2025 compared to the previous year, primarily due to the termination of a business partnership with Peking University International Hospital, which will negatively impact revenue and net profit [2] - The company anticipates a non-recurring expense related to judicial arbitration, which is expected to reduce total profit by approximately 39 million to 45 million yuan [2] - Despite the challenges, the core generic drug business within the pharmaceutical industrial sector is expected to maintain healthy growth, with net profit projected to increase by around 30% compared to the same period last year [3] Group 2 - The company has communicated with its auditing firm regarding the performance forecast, and there are no disagreements between the company and the auditors concerning this forecast [1][2]

Core Viewpoint - The company, Peking University Pharmaceutical (000788.SZ), expects a significant decline in net profit for 2025, with projections indicating a decrease of 47.82% to 33.33% compared to the previous year [1] Financial Performance - The estimated net profit attributable to shareholders for 2025 is projected to be between 72 million to 92 million yuan [1] - The net profit after deducting non-recurring gains and losses is expected to be between 95 million to 115 million yuan, reflecting a year-on-year decline of 25.35% to 9.64% [1] Reasons for Decline - The decline in operating performance is primarily attributed to two factors: 1. The termination of business cooperation between the company's wholly-owned subsidiary, Beijing New Advantage Pharmaceutical Commercial Co., Ltd., and Peking University International Hospital in May 2025, leading to a decrease in revenue and net profit [1] 2. In the pharmaceutical manufacturing sector, the company faces costs related to the handling of personnel due to judicial arbitration, which is expected to reduce total profit by approximately 39 million to 45 million yuan [1]

Core Viewpoint - Peking University Medicine announced an expected decline in net profit for 2025, projecting a range of 72 million to 92 million yuan, which represents a year-on-year decrease of 47.82% to 33.33% [2] Financial Performance - The company anticipates a net profit attributable to shareholders of 72 million to 92 million yuan for 2025 [2] - This projection indicates a significant decline compared to the previous year's performance, with a decrease of 47.82% to 33.33% year-on-year [2]

Core Viewpoint - The company expects a significant decline in net profit for the fiscal year 2025, projecting a range of 72 million to 92 million yuan, which represents a year-on-year decrease of 33.33% to 47.82% [1] Group 1: Business Segments - The pharmaceutical distribution segment is negatively impacted due to the termination of business cooperation between its wholly-owned subsidiary, Beijing New Advantage Pharmaceutical Commercial Co., Ltd., and Peking University International Hospital, effective May 2025, leading to a decrease in revenue and net profit [1] - The pharmaceutical manufacturing segment is expected to incur additional costs related to the handling of personnel affected by judicial arbitration, with an estimated reduction in total profit for the reporting period ranging from 39 million to 45 million yuan [1]

Core Viewpoint - The company, Peking University Pharmaceutical, is forecasting a significant decline in net profit for the year 2025, with expectations of a decrease between 33.33% and 47.82% compared to the previous year [1] Financial Performance - The projected net profit attributable to shareholders for 2025 is estimated to be between 72 million and 92 million yuan [1] - The expected net profit after deducting non-recurring gains and losses is forecasted to be between 95 million and 115 million yuan, reflecting a year-on-year decrease of 9.64% to 25.35% [1] Reasons for Performance Decline - The decline in operating performance is primarily attributed to two factors: 1. The termination of business cooperation between the company's wholly-owned subsidiary, Beijing New Advantage Pharmaceutical Commercial Co., Ltd., and Peking University International Hospital, effective May 2025, which is expected to lead to a decrease in revenue and net profit [1] 2. The impact of expenses related to the disposal of personnel due to judicial arbitration in the pharmaceutical manufacturing sector, which is anticipated to reduce the total profit for the reporting period by 39 million to 45 million yuan [1]

Financial Projections - The estimated net profit attributable to shareholders for 2025 is projected to be between 72 million and 92 million CNY, representing a year-on-year decline of 47.82% to 33.33% compared to 137.99 million CNY in the previous year[3] - The net profit after deducting non-recurring gains and losses is expected to be between 95 million and 115 million CNY, a decrease of 25.35% to 9.64% from 127.26 million CNY in the same period last year[3] - Basic earnings per share are forecasted to be between 0.1208 and 0.1544 CNY, down from 0.2315 CNY in the previous year[3] Business Performance - The decline in operating performance is primarily due to the termination of business cooperation with Peking University International Hospital, leading to a decrease in revenue and net profit[5] - Non-recurring expenses related to judicial arbitration are expected to reduce total profit by approximately 39 million to 45 million CNY[5] - The core generic drug business in the pharmaceutical industrial sector is expected to maintain a healthy growth trend, with net profit increasing by around 30% year-on-year (unaudited)[7] - The stable performance of the core generic drug business has effectively mitigated the impact of the aforementioned performance fluctuations, demonstrating strong resilience in overall business performance[7] - The performance forecast data is based on preliminary estimates by the company's finance department and will be detailed in the 2025 annual report[8]